4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: In vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1948-1964

  Benjahad, Abdellah ^a   Croisy, Martine ^a   Monneret, Claude ^a   Bisagni, Emile ^a   Mabire, Dominique ^b   Coupa, Sophie ^b   Poncelet, Alain ^b   Csoka, Imre ^b   Guillemont, Jérôme ^b   Meyer, Christophe ^b   Andries, Koen ^c   Pauwels, Rudi ^d   De Béthune, Marie Pierre ^d   Himmel, Daniel M ^e   Das, Kalyan ^e   Arnold, Eddy ^e   Chi, Hung Nguyen ^a   Grierson, David S ^a  

^a Laboratoire de Pharmacochimie   (France)

^b Medicinal Chemistry Department   (France)

^c Oncology Drug Discovery   (Belgium)

^d Virco BVBA   (Belgium)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 3 DIMETHLAMINOPYRIDIN 2 ONE; 4 BENZYL 3 DIMETHLAMINOPYRIDIN 2 ONE; 5 (3 METHOXYPROPYL) 6 METHYL 3 DIMETHYLAMINO 4 (3 METHYLBENZOYL)PYRIDIN 2 ONE; 5 (3 METHOXYPROPYL) 6 METHYL 3 DIMETHYLAMINO 4 (3,5 DIMETHYLBENZOYL)PYRIDIN 2 ONE; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN;

ANTI-HIV AGENTS; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 20144370682     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0408621     Document Type: Article

References (44)

1. De Clercq, E. New Developments in Anti-HIV Chemotherapy. Biochim. Biophys. Acta 2002, 1587, 258-275.
2. Lucas, G. M.; Chaisson, R. E.; Moore, R. D. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions. Ann. Intern. Med. 1999, 13, 81-87.
3. Yerly, S.; Kaiser, L.; Race, E.; Bru, J. P.; Clavel, F.; Perrin, L. Transmission of Antiretroviral-Drug-Resistant HIV-1 Variants. Lancet 1999, 354, 729-733.
4. Carr, A.; Samaras, C. K.; Thorisdottir, A.; Kaufmann, G. R.; Ghisholm, D. J.; Cooper, D. A. Diagnosis, Prediction, and Natural Course of HIV-1 Protease Inhibitor Associated Lipodystrophy, Hyperlipidaemia, and Diabetes Mellitus: A Cohort Study. Lancet 1999, 353, 2093-2099.
5. Carr, A.; Cooper, D. A. Adverse Effects of Antiviral Therapy. Lancet 2000, 356, 1423-1430
6. Bastard, J.-P.; Caron, M.; Vidal, H.; Jan, V.; Auclair, M.; Vigouroux, C.; Luboinski, J.; Laville, M.; Maachi, M.; Girard, P.-M.; Rozenbaum, W.; Levan, P.; Capeau, J. Association between Altered Expression of Adipogenic Factor SREBP1 in Lipotrophic Adipose Tissue from HIV-1 Infected Patients and Abnormal Adipocyte Differentiation and Insulin Resistance. Lancet 2002, 359, 1026-1031.
7. Hoffmann, C.; Kamps, B. S. HIV Medicine 2003. http://www.HIV.com, Flying Publisher, 2003.
8. Ruiz, N.; Nusrat, R.; Lauenroth-Mai, E.; Berger, D.; Walworth, C.; Bacheler, L. T.; Ploughman, L.; Tsang, P.; Labriola, D.; Echols, R.; Levy, R. Study DPC 083-203, a Phase II Comparison of 100 and 200 mg Once-Daily DPC 083 and 2 NRTIs in Patients Failing a NNRTI-Containing Regimen. Presented at the 9th Conference on Retroviruses and Opportunustic Infections, Seattle, WA, 2002; Abstract 6.
9. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
10. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Bethune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants. J. Med. Chem. 2004, 47, 2550-2560.
11. (a) Dollé, V.; Fan, E.; Nguyen, C. H.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Jamieson, G.; Tarrago-Litvak, L.; Bisagni, E. A New Series of Pyridinone Derivatives as Potent Non-Nucleoside Human Immunodeficiency Virus Type 1 Specific Reverse Transcriptase Inhibitors. J. Med. Chem. 1995, 38, 4679-4686.
12. (b) Bisagni, E.; Dollé, V.; Nguyen, C.-H.; Legraverend, M.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Tarrago-Litvak, L. 4-Aryl-thio-pyridin-2(1H)-ones, Medecines Containing Them and Their Uses in the Treatment of Illnesses Linked to HIV-1 and 2. WO9705113, 1997.
13. (a) Dollé, V.; Nguyen, C. H.; Legraverend, M.; Aubertin, A.-M.; Kirn, A.; Andreola, M. L.; Ventura, M.; Tarrago-Litvak, L.; Bisagni, E. Synthesis and Antiviral Activity of 4-Benzyl Pyridinone Derivatives as Potent and Selective Non-Nucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors. J. Med. Chem. 2000, 43, 3949-3962.
14. (b) Bisagni, E.; Dollé, V.; Nguyen, C.-H.; Monneret, C.; Grierson, D. S.; Aubertin. A. M. 3-(Amino- or aminoalkyl)pyridinone Derivatives and Their Use for the Treatment of HIV Related Diseases. WO9955676, 1999.
15. Benjahad, A.; Courté, K.; Guillemont, J.; Mabire, D.; Coupa, S.; Poncelet, A.; Csoka, I.; Andries, K.; Pauwels, R.; de Béthune, M.-P.; Monneret, C.; Bisagni, E.; Nguyen, C. H.; Grierson, D. S. 4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones, a New Family of Potent Anti-HIV Agents: Optimization and in Vitro Evaluation against Clinically Important HIV Mutant Strains. J. Med. Chem. 2004, 47, 5501-5514.
16. Hopkins, A. L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; Stuart, D. I.; Stammers, D. K. Design of MKC-442 (Emivirine) Analogues with Improved Activity against Drug-Resistant HIV Mutants. J. Med. Chem. 1999, 42, 4500-4505.
17. Goldman, M. E.; O'Brien, J. A.; Ruffing, T. L.; Schleif, W. A.; Sardana, V. V.; Byrnes, V. W.; Condra, J. H.; Hoffman, J. M.; Emini, A. E. A Nonnucleoside Reverse Transcriptase Inhibitor Active on Human Immunodeficiency Virus Type 1 Isolates Resistant to Related Inhibitors. Antimicrob. Agents Chemother. 1993, 37, 947-949.
18. Saari, W. S.; Hoffman, J. M.; Wai, J. S.; Fisher, T. E.; Rooney, C. S.; Smith, A. M.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Stern, A. M.; Anderson, P. S. 2-Pyridinone Derivatives: A New Class of Nonnucleoside, HIV-1-Specific Reverse Transcriptase Inhibitors. J. Med. Chem. 1991, 34, 2922-2925.
19. Hoffman, J. M.; Wai, J. S.; Thomas, C. M.; Levin, R. B.; O'Brien, J. A.; Goldman, M. E. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1 Specific Reverse Transcriptase Inhibitors. 1. Phthalimido Alkyl and -alkylamino Analogues. J. Med. Chem. 1992, 35, 3784-3791.
20. Saari, W. S.; Wai, J. S.; Fisher, T. E.; Thomas, C. M.; Hoffman, J. M.; Rooney, C. S.; Smith, A. M.; Jones, J. H.; Bamberger, D. L.; Goldman, M. E.; O'Brien, J. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 2. Analogues of 3-Aminopyridin-2(1H)-one. J. Med. Chem. 1992, 35, 3792-3802.
21. Wai, J. S.; Williams, T. M.; Bamberger, D. L.; Fisher, T. E.; Hoffman, J. M.; Hudcosky, R. J.; MacTough, S. C.; Rooney, C. S.; Saari, W. S.; Thomas, C. M.; Goldman, M. E.; O'Brien, J. A.; Emini, E. A.; Nunberg, J. H.; Quintero, J. C.; Schleif, W. A.; Anderson, P. S. Synthesis and Evaluation of 2-Pyridinone Derivatives as Specific HIV-1 Reverse Transcriptase Inhibitors. 3. Pyridyl and Phenyl Analogues of 3-Aminopyridin-2(1H)-one. J. Med. Chem. 1993, 36, 249-255.
22. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
23. Himmel, D.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E. Crystal Structures for HIV-1 Reverse Transcriptase in Complexes with Three Pyridinone Derivatives: A New Class of Non-nucleoside Inhibitors Effective against a Broad Range of Drug-Resistant Strains. Submitted.
24. Paine, J. B., III. A Convenient Synthesis of Nicotinate Ester from 3-Cyanopyridones. J. Heterocycl. Chem. 1987, 24, 351-355.
25. Hoffman, J. M.; Smith, A. M.; Rooney, C. S.; Fisher, T. E.; Wai, J. S.; Thomas, C. M.; Bamberger, D. L.; Barnes, J. L.; Williams, T. M.; Jones, J. H.; Olson, B. D.; O'Brien, J. A.; Goldman, M. E.; Numberg, J. H.; Quintero, J. C.; Schleif, W. A.; Emini, A. E. Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and Analogs. J. Med. Chem. 1993, 36, 953-966.
26. Elgemeie, G. E. H.; Attia, A. M. E.; Hussain, B. A. W. A Synthetic Strategy to a New Class of Cycloalkane Ring-Fused Pyridine Nucleosides as Potental Anti-HIV Agents. Nucleosides Nucleotides 1998, 17, 855-868.
27. Sybyl Discovery Software, version 6.5; Tripos Inc.: St. Louis, MO (http://www.tripos.com/).
28. Pauwels, R.; Balzarini, J.; Baba, M.; Snoek, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and Automated Tetrazolium-Based Calorimetric Assay for the Detection of Anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.
29. Perola, E.; Charifson, P. S. Conformational Analysis of Drug-Like Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding. J. Med. Chem. 2004, 47, 2499-2510.
30. Rodgers, D. W.; Camblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The Structure of Unliganded Reverse Transcriptase from the Human Immunodefficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
31. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Arnold, E. Structure of Unliganded HIV-1 Reverse Transcriptase at 2.7 Å Resolution: Impactions of Conformational Changes for Polymerization and Inhibition Mechanisms. Structure 1996, 4, 853-860.
32. (a) Ding, J.; Das, K.; Hsiou, Y.; Zhang, W.; Arnold, E. Structural Studies of HIV-1 Reverse Transcriptase and Implications for Drug Design. In Structure-Based Drug Design; Veerapandian, P., Ed.; Marcel Dekker, Inc.: New York, 1997; pp 41-82.
33. (b) Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. L.; Stammers, D. K. Structural Mechanisms of Drug Resistance for Mutations at Codons 181 and 188 in HIV-1 Reverse Transcriptase and the Improved Resilience of Second Generation Non-Nucleoside Inhibitors. J. Mol. Biol. 2001, 312, 795-805.
34. (c) Ren, J.; Nichols, C.; Chamberlain, P.; Weaver, K.; Short, S.; Stammers, D. K. Crystal Structures of HIV-1 Reverse Transcriptase Mutated at Codons 100, 106, and 108 and Mechanisms of Resistance to Non-Nucleoside Inhibitors. J. Mol. Biol. 2004, 336, 569-578.
35. (d) Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D., Jr.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P. A. J.; Boyer, P. L.; Clark, P.; Smith, R. H., Jr.; Smith, M. B. K.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal Structures of 8-Cl and 9-Cl TIBO Complexed with Wild-Type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-Resistant Mutant. J. Mol. Biol. 1996, 264, 1085-1100.
36. (e) Hsiou, Y.; Das, K.; Ding, J.; Clark, A. D., Jr.; Kleim, J.-P.; Rösner, M.; Winkler, I.; Riess, G.; Hughes, S. H.; Arnold, E. Structures of Tyr188Leu Mutant and Wild-Type HIV-1 Reverse Transcriptase Complexed with the Non-nucleoside Inhibitor HBY 097: Inhibitor Flexibility Is a Useful Design Feature for Reducing Drug Resistance. J. Mol. Biol. 1998, 284, 313-323.
37. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Wilcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. J. Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
38. Estel, F. L.; Marsais, F.; Godard, A.; Quéguiner, G. Synthesis of Ortho-Substitued Aminopyridines Methalation of Pivaloylamino Derivatives. J. Heterocycl. Chem. 1989, 26, 105-112.
39. Pomel, V.; Rovera, J. C.; Godard, A.; Marsais, F.; Quéguiner, G. Synthesis of New Pyridine Intermediates as Precursors for the Elaboration of Sterptonigrin Analogues by the Metalation-Cross-Coupling Strategy. J. Heterocycl. Chem. 1996, 33, 1995-2005.
40. Kapalka, G.-D.; Slayden, S. Directive Effects in the Hydroboration of Isomeric Methoxy-2-hexynes. J. Organomet. Chem. 1975, 93, 33-38.
41. Terasawa, T.; Okada, T. Reaction of Mixed Carboxylic Anhydrides with Grignard Reagents: Application to the Preparation of Keto Esters; Scope and Limitations. Tetrahedron 1997, 33, 595-598.
42. Florent, J. C.; Gaudel, G.; Monneret, C.; Hoffmann, D.; Kraemer, H.-P. Synthesis and Antitumor Activity of Isodoxorubicin Analogues. J. Med. Chem. 1993, 36, 1364-1368.
43. Hollywood, C. J.; Ley, S. V.; Yamanoi, S. Synthesis of Taurospongin: A Potent Inhibitor of DNA Polymerase and HIV Reverse Transcriptase, Using π-Allyltricarbonyliron Lactone. Chem. Commun. 2002, 15, 1624-1625.
44. Hertogs, K.; de Bethune, M. P.; Miller, V.; Ivens, T.; Schel, P.; Van Cauwenberge, A.; Van Den Eynde, C.; Van Gerwen, V.; Azijn, H.; Van Houtte, M.; Peeters, F.; Staszewski, S.; Conant, M.; Bloor, S.; Kemp, S.; Larder, B.; Pauwels, R. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrob. Agents Chemother. 1998, 42, 269-276.